Breaking News
Get 50% Off 0
👀 Ones to watch: The MOST undervalued shares to buy right now
See Undervalued Shares
Close

Saratoga Health & Biotechnology Portfolio Fund Class Institutional (SBHIX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
22.830 -0.100    -0.44%
27/12 - Closed. Currency in USD
  • Morningstar Rating:
  • Total Assets: 5.87M
Type:  Fund
Market:  United States
Issuer:  Saratoga
Asset Class:  Equity
Saratoga Health Biotechnology Portfolio Fund Cla 22.830 -0.100 -0.44%

SBHIX Overview

 
On this page you'll find an in-depth profile of Saratoga Health & Biotechnology Portfolio Fund Class Institutional. Learn about the key management, total assets, investment strategy and contact information of SBHIX among other information.
Category

Health

Total Assets

5.87M

Expenses

2.32%

Inception Date

Jan 28, 2003

Investment Strategy

The investment seeks long-term capital growth. The fund will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or "market capitalization"). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends.

Contact Information

Address 99 Wall Street, Suite 1200
New York,NY 10005
United States
Phone +1 8008073863

Top Executives

Name Title Since Until
Robert D. Stimpson Analyst 2019 Now
Biography Robert D. Stimpson, CFA, CMT. Mr. Stimpson is Co-Chief Investment Officer and a Portfolio Manager at Oak Associates, which he joined in 2001. Prior to joining Oak Associates in 2001, Mr. Stimpson earned an MBA from Emory University. Previously, Mr. Stimpson worked as an Equity Market Analyst for I.D.E.A., ltd and for Merrill Lynch as a Financial Consultant. He has been with the investment industry since 1997. In addition to the CFA designation, Mr. Stimpson holds the CMT charter from the Market Technicians Association.
Mark W. Oelschlager Founder 2005 2019
Biography Mark W. Oelschlager, CFA founded Oelschlager Investments in 2019 and serves as the firm’s President and Chief Investment Officer. Prior to 2019, he served as Co-Chief Investment Officer of Oak Associates, ltd. He was Portfolio Manager of Pin Oak Equity Fund, Live Oak Health Sciences Fund, and Red Oak Technology Select Fund, as well as Co-Portfolio Manager of White Oak Select Growth Fund. Prior to joining Oak Associates in 2000, Mr. Oelschlager served as a Senior Securities Analyst for the State Teachers Retirement System of Ohio. Mr. Oelschlager holds a BA in Economics from Trinity College, an MBA from The Ohio State University and the Chartered Financial Analyst (CFA) designation. He has been in the investment industry since 1994.
Brandi K. Allen Sector Portfolio Manager 2005 2006
Biography Brandi serves as Portfolio Manager for the Focused Large Cap Growth and serves as a Sector Portfolio Manager with Consumer Staples and Healthcare sector responsibilities. Prior to joining Silvant in 2006, Ms. Allen worked at Oak Associates where she was Co-Portfolio Manager for a healthcare biotech fund and a small cap growth fund. She earned a Bachelor of Business Administration with honors in Finance from Ohio University (1997) and her Masters of Business Administration from Case Western Reserve University (2000). Brandi has worked in investment management since 1997.
Management Team - 2003 2005
Biography Team Managed
Gregory Aurand Senior Analyst, Portfolio Manager 2001 2002
Biography Aurand joined Orbitex Management, Inc. in 2001 from Munder Capital Management. From 1995 to 2001, Mr. Aurand was a senior equity analyst and portfolio manager at Munder.
Alidad Mireskandari Portfolio Manager 2001 2002
Biography Mireskandari, is a portfolio manager with Orbitex Management. He joined the firm in 2001 from Monument Advisors. Before joining Monument he was a manager in the Life Sciences Industry Group at Pittiglio Rabin Todd & McGrath. Prior, he worked evaluating strategic business opportunities for Fisher Scientific, and as a research fellow at NIH's National Cancer Institute.
Timothy F. Bepler Senior Analyst 1999 2001
Biography Bepler serves as vice president and portfolio manager with Orbitex Management, his employer since 1999. Previously, he was a vice president with Merrill Lynch Asset Management as a health care analyst. Prior to that, he was the sole health care analyst for a division of Credit Suisse and a senior analyst with Value Line. He is a member of the New York Society of Security Analysts and the Association for Investment Management and Research. Bepler holds the Chartered Financial Analyst designation.
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SBHIX Comments

Write your thoughts about Saratoga Health & Biotechnology Portfolio Fund Class Institutional
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email